Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $9.1, reflecting a period of significant pressure for the biopharmaceutical company. With a market ...

HC Wainwright reiterated their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report report published on Wednesday,Benzinga reports. The brokerage currently ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP shed 2.58% to $6.79 Friday, on what proved to be an all-around positive ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP advanced 1.03% to $6.84 Wednesday, on what proved to be an all-around ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $7.87, with InvestingPro data showing the stock is currently trading below its Fair... In a recent ...

NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval ...

Investors in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 17, ...

NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval ...